• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大剂量6-巯基嘌呤和甲氨蝶呤输注对急性淋巴细胞白血病巩固治疗期间转甲基作用的影响。

Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.

作者信息

Keuzenkamp-Jansen C W, De Abreu R A, Blom H J, Bökkerink J P, Trijbels J M

机构信息

Laboratory of Pediatrics, University Hospital St. Radboud, Nijmegen, The Netherlands.

出版信息

Biochem Pharmacol. 1996 May 3;51(9):1165-71. doi: 10.1016/0006-2952(96)00032-9.

DOI:10.1016/0006-2952(96)00032-9
PMID:8645339
Abstract

6-mercaptopurine (6MP) cytotoxicity is caused by thioguanine and methylthioinosine nucleotides. Thiopurine methylation occurs to a large extent in vivo and in vitro. In this reaction, S-adenosyl-L-methionine (AdoMet), produced from methionine and ATP, is converted into S-adenosyl-L-homocysteine (AdoHcy) which, in turn, is hydrolyzed into homocysteine. Remethylation of homocysteine into methionine is inhibited by methotrexate (MTX). In cultured lymphoblasts, AdoMet: AdoHcy ratio and DNA methylation decrease after incubation with 6MP. The aim of the present study was to investigate the influence of high-dose 6MP on the methylation capacity in children with acute lymphoblastic leukemia. Five patients received 4 courses with high-dose intravenous MTX (5' g.m-2 in 24 hr) immediately followed by high-dose 6MP (1300 mg.m-2 in 24 hr). Five control patients received high-dose MTX and oral 6MP (25 mg.m -2 daily for 8 weeks). Leucovorin rescue was started at 36 hr in both groups. In the intravenous 6MP group, 6-methylmercaptopurine, its riboside, and 6-methylmercapto-8-hydroxypurine were detectable in plasma in concentrations of 0.3-2.6 muM (6MP steady state levels: 11.6 muM). In red blood cells, mean methylthioinosine nucleotide levels were one third of those of ATP (13.1 nmol/10(8)). AdoHcy levels (10 pmol/10(8)) remained constant in both groups and AdoMet was not detectable ( < 20 pmol/10(8)). In both groups, plasma homocysteine increased and methionine decreased following administration of MTX. The delay in the recovery of methionine in the intravenous 6MP group after MTX infusion is probably the result of an increased demand on methyl groups during 6MP infusion.

摘要

6-巯基嘌呤(6MP)的细胞毒性由硫鸟嘌呤和甲硫基肌苷核苷酸引起。硫嘌呤甲基化在体内和体外均大量发生。在该反应中,由甲硫氨酸和ATP产生的S-腺苷-L-甲硫氨酸(AdoMet)转化为S-腺苷-L-高半胱氨酸(AdoHcy),而后者又水解为高半胱氨酸。高半胱氨酸再甲基化为甲硫氨酸的过程受到甲氨蝶呤(MTX)的抑制。在培养的淋巴母细胞中,与6MP孵育后,AdoMet:AdoHcy比值和DNA甲基化降低。本研究的目的是调查高剂量6MP对急性淋巴细胞白血病患儿甲基化能力的影响。5例患者接受4个疗程的高剂量静脉注射MTX(24小时内5 g.m-2),随后立即给予高剂量6MP(24小时内1300 mg.m-2)。5例对照患者接受高剂量MTX和口服6MP(每日25 mg.m -2,共8周)。两组均在36小时开始亚叶酸解救。在静脉注射6MP组中,血浆中可检测到6-甲基巯基嘌呤、其核苷和6-甲基巯基-8-羟基嘌呤,浓度为0.3 - 2.6 μM(6MP稳态水平:11.6 μM)。在红细胞中,甲硫基肌苷核苷酸的平均水平是ATP的三分之一(13.1 nmol/10(8))。两组中AdoHcy水平(10 pmol/10(8))保持恒定,且未检测到AdoMet(< 20 pmol/10(8))。两组在给予MTX后血浆高半胱氨酸均升高,甲硫氨酸均降低。MTX输注后静脉注射6MP组中甲硫氨酸恢复延迟可能是6MP输注期间甲基需求增加的结果。

相似文献

1
Effects on transmethylation by high-dose 6-mercaptopurine and methotrexate infusions during consolidation treatment of acute lymphoblastic leukemia.大剂量6-巯基嘌呤和甲氨蝶呤输注对急性淋巴细胞白血病巩固治疗期间转甲基作用的影响。
Biochem Pharmacol. 1996 May 3;51(9):1165-71. doi: 10.1016/0006-2952(96)00032-9.
2
6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.6-巯基嘌呤的剂量和药代动力学影响急性淋巴细胞白血病患儿大剂量甲氨蝶呤治疗后的骨髓毒性程度。
Leukemia. 2001 Jan;15(1):74-9. doi: 10.1038/sj.leu.2401986.
3
Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.大剂量甲氨蝶呤治疗儿童急性白血病后的骨髓毒性受6-巯基嘌呤剂量影响,但不受硫嘌呤甲基转移酶中间活性影响。
Cancer Chemother Pharmacol. 2015 Jan;75(1):59-66. doi: 10.1007/s00280-014-2613-7. Epub 2014 Oct 28.
4
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.6-巯基嘌呤剂量强度在急性淋巴细胞白血病中的预后重要性。
Blood. 1999 May 1;93(9):2817-23.
5
Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.甲氨蝶呤/6-巯基嘌呤维持治疗儿童急性淋巴细胞白血病的骨髓毒性、药代动力学及复发率
Pediatr Hematol Oncol. 1996 Sep-Oct;13(5):433-41. doi: 10.3109/08880019609030855.
6
Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity.急性淋巴细胞白血病或伯基特淋巴瘤患儿大剂量甲氨蝶呤治疗后的血浆同型半胱氨酸、蛋氨酸和S-腺苷同型半胱氨酸水平:与肝毒性的关联
Leuk Lymphoma. 2014 Jul;55(7):1591-5. doi: 10.3109/10428194.2013.850684. Epub 2013 Nov 14.
7
Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.巯嘌呤代谢物水平是儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗后骨髓毒性的预测指标。
Cancer Chemother Pharmacol. 2015 May;75(5):1089-93. doi: 10.1007/s00280-015-2717-8. Epub 2015 Mar 19.
8
Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.硫嘌呤类药物治疗儿童白血病:遗传性硫嘌呤甲基转移酶活性对药物代谢和细胞毒性的影响。
Br J Clin Pharmacol. 1997 Nov;44(5):455-61. doi: 10.1046/j.1365-2125.1997.t01-1-00607.x.
9
Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).口服甲氨蝶呤和6-巯基嘌呤的早晨与晚上给药方案对急性淋巴细胞白血病患儿复发风险的影响。北欧儿科血液学和肿瘤学会(NOPHO)。
J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):102-9. doi: 10.1097/00043426-199703000-00002.
10
Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.两名硫嘌呤甲基转移酶缺乏患者的药代动力学、剂量调整及6-巯基嘌呤/甲氨蝶呤药物相互作用
Acta Paediatr. 1998 Jan;87(1):108-11. doi: 10.1080/08035259850158001.